About E3 ubiquitin-protein ligase RING2
E3 ubiquitin-protein ligase RING2 (RNF2) is a protein
from Homo sapiens identified by UniProt accession
Q99496, 336 residues long.
MolForge cross-references it against 0 known binders and
114 disease associations.
Target properties
| Protein name | E3 ubiquitin-protein ligase RING2 |
|---|
| UniProt accession | Q99496 |
|---|
| Gene | RNF2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 336 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (114)
Diseases linked to this target (Open Targets).
- Luo-Schoch-Yamamoto syndrome · score 0.53
- complex neurodevelopmental disorder · score 0.37
- neurodegenerative disease · score 0.35
- breast adenocarcinoma · score 0.26
- glioblastoma multiforme · score 0.26
- endometrial cancer · score 0.25
- cystatin C measurement · score 0.21
- head and neck squamous cell carcinoma · score 0.19
- lung adenocarcinoma · score 0.19
- epilepsy · score 0.18
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q99496-F1 | alphafold | PREDICTED | 77.38 | — |
Amino-acid sequence (336 residues)
MSQAVQTNGT QPLSKTWELS LYELQRTPQE AITDGLEIVV SPRSLHSELM CPICLDMLKN TMTTKECLHR FCADCIITAL RSGNKECPTC RKKLVSKRSL RPDPNFDALI SKIYPSRDEY EAHQERVLAR INKHNNQQAL SHSIEEGLKI QAMNRLQRGK KQQIENGSGA EDNGDSSHCS NASTHSNQEA GPSNKRTKTS DDSGLELDNN NAAMAIDPVM DGASEIELVF RPHPTLMEKD DSAQTRYIKT SGNATVDHLS KYLAVRLALE ELRSKGESNQ MNLDTASEKQ YTIYIATASG QFTVLNGSFS LELVSEKYWK VNKPMELYYA PTKEHK
Explore E3 ubiquitin-protein ligase RING2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets